#amrn

New hope for investors as Amarin (AMRN) sees a promising year ahead

Though Amarin Corporation (NASDAQ: AMRN) has been showing signs of recovery since last year, after staying low for several years, the stock has a long way to go before restoring investors’ confidence. The biotech firm got a fresh boost this week after the management issued an update to its estimates for fiscal 2019.

Guidance Lifted

Currently, revenues are expected to be above the upper…

Where is Amarin (AMRN) headed after FDA panel favors Vascepa’s label expansion

Biotech firm Amarin Corporation (NASDAQ: AMRN) had a positive start to the week, with the shares making sharp gains and hitting the highest level in more than a decade. Though initially there was speculation as to where the stock is headed, the rally gathered momentum towards the end of the week after an FDA committee unanimously voted in favor of label expansion for Vascepa, the company’s…

Amarin reports revenue growth of 103% in Q3

Amarin Corporation plc (NASDAQ: AMRN) reported total revenue of $112.4 million for the third quarter of 2019, up 103% compared to the prior-year period.

GAAP net loss was $3.5 million, or $0.01 per share, compared to a loss of $24.5 million, or $0.08 per share, last year. Adjusted net income was $4.5 million, or $0.01 per share.

(This story will be updated shortly)

Motley Fool: Amarin: Keep Your Dry Powder Ready

Even though I’m an unabashed bull for Amarin (NASDAQ:AMRN), I’ve never bought a single share of this promising biotech stock. The reason is that I’ve been waiting for a specific buying opportunity. Namely, the company’s upcoming advisory committee meeting for its prescription omega-3 pill, Vascepa, tentatively scheduled for Nov. 14. 

The key issue is that Amarin’s shares are almost certain to…

Amarin’s stock gains on Q2 results beat

Amarin Corporation plc (NASDAQ: AMRN) reported better-than-expected revenue and earnings for the second quarter of 2019, allowing the stock to gain 2.2% in premarket hours on Wednesday. The consensus estimate was for a loss of $0.02 per share on revenue of $99.5 million.  

Total revenue grew nearly 92% to $100.8 million compared to the same period last year. Net product revenue increased 91%…

Amarin updates 2019 revenue guidance on strong Vascepa sales, stock soars

Amarin (NASDAQ: AMRN) said sales of its fat-reducing drug Vascepa were far better in the first half of 2019 than it had originally anticipated. The strong sales witnessed in the first six months of the year has prompted the Irish biopharmaceutical firm to raise its total 2019 revenue guidance to a range of $380 million to $420 million from the prior projection of $350 million.

Wall Street…

Amarin Corp reports Q1 2019 earnings results

Amarin Corporation (NASDAQ: AMRN) on Wednesday said its revenues soared 67% to $73.3 million, riding on the strong demand for its Vascepa capsules as well as receive higher commercialization fees from its licensed partners. The topline surpassed Wall Street projection of $72.2 million.

The company, however, reported a loss of 5 cents per share during the quarter, as it incurred more expenses…